Research Paper Volume 12, Issue 12 pp 11364—11385

Sirt1 gene confers Adriamycin resistance in DLBCL via activating the PCG-1α mitochondrial metabolic pathway

class="figure-viewer-img"

Figure 1. Sirt1 protein is overexpression in DLBCL patients, especially in Non-GCB DLBCL tissues. (A) Immunohistochemistry (IHC) staining indicates that Sirt1 protein expression is upregulated in DLBCL patients, compared with that of normal lymph nodes (non-tumor). A representative sample (GCB-DLBCL: 36; Non-GCB DLBCL: 38; Normal: 10) is shown (200 ×). (B) Scatter diagrams of Sirt1 protein expression in DLBCL patients indicated using immunoreactive scores. (C) Western blotting analysis of Sirt1 expression in three normal lymph node (non-tumor), four primary GCB-DLBC tissues (p1, p2, p3 and p4) and four primary Non-GCB DLBCL tissues (p5, p6, p7 and p8). (D) Western blotting was used to detect Sirt1 expression in CD19+ purified peripheral blood from normal B cells, GCB-DLBCL cell lines (LY7 and LY19 cells), Non-GCB DLBCL cell lines (LY3 and LY10 cells) and normal lymph nodes (non-tumor); Each sample was normalized to β-actin expression. All experiments were performed in triplicate. * indicates p<0.05 against control group.